Evidence map›Paper›PMID 40153090›Full record

ArticleMetabolic brain disease2025

Protective effects of alpha-lipoic acid on memory deficit induced by repeated doses of solifenacin in mice: the role of nitro-oxidative stress.

Leonardo Pimentel Dantas, Emanuel Carneiro de Vasconcelos, Carla da Silva Cunha, Pauliane Valeska Chagas Batista, Morgana Carla Souza Torres, Caren Nádia Soares de Sousa, Gabriel Angelo de Aquino, Manuel Alves Dos Santos Junior, Pedro Henrique Freitas de Rezende, Wilson Silva de Vasconcelos and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leonardo Pimentel DantasLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0003-3452-0592
Emanuel Carneiro de VasconcelosLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0001-8516-1804
Carla da Silva CunhaLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0001-5044-1312
Pauliane Valeska Chagas BatistaLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0003-1212-1021
Morgana Carla Souza TorresLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0002-3846-3401
Caren Nádia Soares de SousaLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0001-5409-0441
Gabriel Angelo de AquinoLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0001-7139-3380
Manuel Alves Dos Santos JuniorLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0003-4217-8950
Pedro Henrique Freitas de RezendeLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0002-6252-7698
Wilson Silva de VasconcelosLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.ORCID 0000-0003-4614-300X
Manoel Cláudio Azevedo PatrocinioDepartment of Anesthesiology, Instituto Dr. Jose Frota, Fortaleza, CE, Brazil.ORCID 0000-0002-6194-6516
Silvânia Maria Mendes VasconcelosLaboratory of Neuropsychopharmacology, Center for Research and Development of Medicines, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil. silvania_vasconcelos@yahoo.com.br.ORCID 0000-0003-1478-0127

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solifenacin (Sol) is one of the most used antimuscarinics for the treatment of bladder dysfunction and there are no conclusive studies on its effects on learning and memory after long-term use. Since substances with antioxidant action, such as alpha-lipoic acid (ALA), have shown protective action in memory deficit and Alzheimer's disease, we decided to study the effects of Sol alone or associated with ALA in behavioral tests of memory and its relation to nitro-oxidative stress in different brain areas. Mice received saline or Sol p.o. for 14 or 28 days. ALA groups received: (a) saline + ALA, (b) Sol for 14 days and Sol + ALA from the 15th to the 28th days and, (c) Sol + ALA for 28 days. Behavioral tests were performed and oxidative changes (lipid peroxidation) and nitrite in the prefrontal cortex (PFC), hippocampus (HC) and striatum (ST) were also determined. Sol produced memory alterations in the mice, reducing the step-down latency and the recognition index in the novel object recognition test. Sol also increased lipid peroxidation in PFC, HC and ST and nitrite levels in the HC. On the other hand, ALA associated with Sol was able to restrict the effects caused by Sol alone, both in relation to nitro-oxidative parameters and in relation to behavioral tests. Taken together, our data suggest that ALA can be administered as an adjunctive drug in patients requiring prolonged use of Sol to mitigate these adverse central nervous system effects. However, clinical studies need to be performed to corroborate preclinical research.

Indexed as

AntioxidantsMemory DisordersMuscarinic AntagonistsOxidative StressSolifenacin SuccinateThioctic AcidAnimalsBrainHippocampusLipid PeroxidationMaleMemoryMiceAntioxidantsMuscarinic AntagonistsSolifenacin SuccinateThioctic AcidBehaviorBrainMemoryNitro-oxidative stressSolifenacin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.